13 11 20

Information and support

  • Get informed
  • Get support
  • Cut my risk
  • Get involved
  • Research
  • PALLAS

    Acronym: 

    PALLAS

    ACTRN/NCT /ethics: 

    NCT02513394

    Scientific title: 

    PALbociclib CoLlaborative Adjuvant Study: A Randomized Phase III Trial of Palbociclib With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone for Hormone Receptor Positive (HR+) / Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Early Breast Cancer

    Summary of trial and patient characteristics

    Cancer Type Breast
    Trial Type Treatment
    Phase Phase III Tumour Stream Breast
    Age Range 18 years and older Cancer Stage In Situ
    Sex Both Anticipated Start Date 2015-08-01
    Molecular Target Anticipated End Date 2025-09-01
    Cancer Type Breast
    Trial Type Treatment
    Phase Phase III
    Age Range 18 years and older
    Sex Both
    Molecular Target
    Tumour Stream Breast
    Cancer Stage In Situ
    Anticipated Start Date 2015-08-01
    Anticipated End Date 2025-09-01

    Trial Summary

    PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with adjuvant endocrine therapy versus endocrinetherapy alone for hormone receptor positive (HR+)/ human epidermal growth factor receptor 2 (HER2)-negative early breast cancer.

    Lay Summary

    PALbociclib CoLlaborative Adjuvant Study: A Randomized Phase III Trial of Palbociclib With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone for Hormone Receptor Positive (HR+) / Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Early Breast Cancer

    Sponsor / Cooperative group

    Alliance Foundation Trials, LLC

    Participating Hospitals

    Hospital Clinical Trial Coordinator Email Phone Principal Investigator Recruitment Status
    Flinders Medical Centre Alex Scott-Hoy alex.scott-hoy@sa.gov.au 08 8204 4830 Bogda Koczwara Recruiting